We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

The proposed directors includes former leaders at US LBM, Univar Solutions, Dow, FedEx, Flexsteel, Owens Corning and Trane.

Nsight Fleet enables third-party logistics sites to provide power for refrigerated trailers from multiple carriers and ...

Carboline has named Priscila Nobre as the company’s inaugural Vice President of Supply Chain. She will oversee the company’s ...

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Both Qualcomm and Arm Holdings trade lower after earnings, Skyworks says its share of the business to supply Apple will fall and cut into revenue, and Ford Motor’s operating profit forecast ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.